Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Payables: 2015-2024

Historic Payables for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $288,000.

  • Cartesian Therapeutics' Payables rose 330.37% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 44.02%. This contributed to the annual value of $288,000 for FY2024, which is 90.86% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Payables of $288,000 as of FY2024, which was down 90.86% from $3.1 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Payables high stood at $3.1 million for FY2023, and its period low was $224,000 during FY2021.
  • Its 3-year average for Payables is $1.3 million, with a median of $316,000 in 2022.
  • As far as peak fluctuations go, Cartesian Therapeutics' Payables skyrocketed by 896.84% in 2023, and later plummeted by 90.86% in 2024.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Payables stood at $443,000 in 2020, then plummeted by 49.44% to $224,000 in 2021, then surged by 41.07% to $316,000 in 2022, then soared by 896.84% to $3.1 million in 2023, then plummeted by 90.86% to $288,000 in 2024.